






















































Endothelial barrier integrity in COVID-19-
dependent hyperinflammation: does the
protective facet of platelet function matter?
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The characteristic feature of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection (COVID-19 disease) is that
its course is asymptomatic or mild in the majority of cases, while
increasing age and/or underlying cardiovascular diseases predispose
for a severalfold increased case fatality rate.1 This association has
not been explained as yet, and several potential mechanisms have
been put forward to uncover why the course of the disease is
more severe in elderly patients with underlying cardiovascular risk
factors and/or cardiovascular diseases. Some hypotheses have been
proposed, including the role of angiotensin-converting enzyme 2
(ACE2) (a functional receptor for SARS-CoV-2), accelerated ageing
of the immune system, or other mechanisms linked to comorbid-
ities.1 However, it has been recently reported that SARS-CoV-2 vi-
rus-induced endotheliitis and microvascular endothelium pathology
could contribute to vascular bed dysfunction in different organs
and to fatal clinical sequelae in COVID-19 patients.2 Indeed, in
patients who died from COVID-19, severe endothelial injury, wide-
spread thrombosis, and microangiopathy were detected,3 pointing
to the important role of vascular pathophysiology and alterations
in endothelial function in COVID-19 disease. In fact, a biomarker
of endothelial activation and altered endothelial permeability,
angiopoietin-2, was found to be a good predictive factor for severe
cases of COVID-194 disease underscoring important pathophysio-
logical role of vascular endothelial dysfunction in COVID-19, with
its distinct vascular endotype.5
Here we suggest that the severity of COVID-19, increasing with
patient age and/or the presence of cardiovascular comorbidities,
might also be associated with the impairment of platelet-dependent
mechanisms preserving the integrity of the endothelial barrier.
Indeed, platelet-dependent endothelium-protective mechanisms
play an important role in acute and chronic inflammatory condi-
tions,6 and might safeguard the endothelial barrier of the
pulmonary microcirculation alongside COVID-19-induced hyperin-
flammation. These protective mechanisms might be hampered or
lost, particularly in patients with pre-existing endothelial
dysfunction with inhibited platelet function or evolving thrombocy-





Mechanisms of classical haemostasis activated in response to vascular in-
jury and contributing to cardiovascular diseases are well known. They in-
volve binding of the GPIb–IX–V complex on platelets to immobilized
von Willebrand factor and platelet GPVI binding to collagen, thrombox-
ane A2 production, ADP release, as well as activation of the platelet
GPIIb/IIIa receptor with subsequent prothrombinase complex formation
and thrombin generation to convert soluble fibrinogen into fibrin
(Figure 1A). However, platelet-dependent mechanisms are also involved
in the protection of the endothelial barrier in acute and chronic inflam-
mation in the processes that have been recently termed as non-classical
inflammation-associated haemostasis.6 In fact, platelets that participate in
the early immune response serve as gatekeepers of the vascular wall,
protecting the endothelial barrier against leaks, subsequent bleeding, and
excessive inflammatory damage.6 The mechanisms of platelet-
dependent maintenance of endothelial barrier integrity also seem to be
critical in the context of viral infections as their impairment results in
bleeding and vascular damage.8 Platelet-dependent mechanisms main-
taining endothelial barrier also operate in a number of other conditions,
including bacterial infections, injection of immune complexes and irri-
tants, ischaemia–reperfusion, and irradiation,6 and may be of importance
in cancer-related inflammation, as recently reviewed by us.9
The mechanisms by which platelets preserve vascular integrity and
prevent inflammatory bleeding are not well understood. Although they
initially seemed to be quite distinct and independent from coagulation-
related mechanisms, recent evidence suggests that they overlap with
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..classical prothrombotic platelet pathways. Platelets may prevent inflam-
matory bleeding by (i) the release of endothelium-stabilizing factors
from platelet granules; (ii) the activation of platelet C-type lectin recep-
tor CLEC-2 containing the hemITAM motif (binding to podoplanin or
S100A13) or the activation of the platelet collagen GPVI receptor associ-
ated constitutively with the FcRc; (iii) by direct interaction of single plate-
lets plugging the exit sites for erythrocytes within the endothelial
monolayer (Figure 1B)6,9.
Platelets safeguard the integrity of
the pulmonary microcirculation
It is increasingly recognized that patients with COVID-19 are at signifi-
cant risk of thrombo-embolic complications affecting the arterial and ve-
nous vascular systems, as well as the pulmonary circulation,3 and,
therefore, various thromboprophylactic regimens are recommended.10
Increased SARS-CoV-2 infection-induced risk of thrombosis seems to
result from excessive platelet activation, endothelial dysfunction, and sta-
sis.2,3 On the other hand, severe COVID-19 disease features exagger-
ated systemic inflammation associated with cytokine storm
characterized by multiple organ failure, including the lungs affected by
acute respiratory distress syndrome (ARDS).11 The intensity of the in-
flammatory response is closely linked to mortality, as shown by retro-
spective clinical studies revealing that non-survivors exhibited higher
levels of interleukin-6 (IL-6), ferritin, and C-reactive protein (CRP).12
Furthermore, pulmonary endothelium may play a central role in the
pathogenesis of ARDS related to COVID-19, not only by altering vessel
integrity but also by fostering procoagulative and proinflammatory pro-
cesses, as well as by gate-keeping of the immune response to virus infec-
tion.13 Therefore, it is tempting to suspect that mechanisms of non-
classical platelet-dependent inflammation-associated haemostasis could
be of key importance with respect to endothelial barrier integrity in the
pulmonary circulation in COVID-19.
Indeed, platelet-dependent mechanisms have been shown to pre-
serve pulmonary vascular integrity in health and alongside an inflam-
matory disease, as evidenced by induction of thrombocytopenia that
increased permeability of the pulmonary microcirculation in several
experimental models, such as isolated perfused sheep and rabbit
lungs, and in in vivo murine models of bacterial pneumonia-induced
sepsis and lipopolysaccharide-induced acute lung injury.14 These
observations were supported by in vitro experiments whereby isolated
human platelets reduced the permeability of endothelial cell mono-
layers.14 Vascular leak associated with low platelet counts was also
reported in a patient with mild thrombocytopenia in inflamed skin
areas following a sunburn insult.14 Finally, in a recent study, Lax and
colleagues demonstrated in the mouse model of ARDS that platelet
CLEC-2 protected against lung injury and subsequent inflammation-
induced alveolar capillary permeability via effects of its ligand podopla-
nin on inflammatory alveolar macrophages.11 Altogether, solid evi-
dence supports the role of platelets in the protection of vascular
integrity, and novel mechanisms of platelet-dependent protection
Figure 1 Prothrombotic and protective facets of platelet function that both could be of importance in SARS-CoV-2 infection. (A) Platelet-dependent
mechanisms leading to thrombus formation involve activation of classical platelet receptors: TP (thromboxane receptor), P2Y12 (ADP receptor), PAR
(thrombin receptors), GPIb–IX–V (von Willebrand receptor), GPVI (collagen receptor), and GPIIb/IIIa (fibrinogen receptor). (B) Platelet-dependent mecha-
nisms of inflammation-associated haemostasis preventing bleeding associated with inflammation are stimulus and organ dependent and may involve the
platelet hemITAM receptor CLEC-2 activated by podoplanin (expressed, for example, on activated monocytes), platelet ITAM FcRc receptor functionally
associated with platelet collagen receptor GPVI, platelet secretion of factors supporting the endothelial barrier (angiopoetin-1), and/or direct sealing of the
hole within the endothelial monolayer by platelets.6,9,11,15


































































.against passive fluid leakage in inflammation based on platelet-derived
angiopetin-1 are emerging.15 The safeguarding role of platelets might
be of particular importance in the acute inflammatory lung response
to infection, as summarized in an excellent review by Middleton and
colleagues.14
Summary
Based on the evidence supporting platelet-dependent mechanisms pro-
tecting endothelial barrier integrity in inflammation, it is tempting to
speculate that increased microcirculation permeability associated with
thrombocytopenia or prolonged use of antiplatelet agents and pre-
existising endothelial dysfunction of cardiovascular diseases may contrib-
ute to the increased severity of COVID-19-related ARDS. Given the
age-related decline of the endothelial barrier and platelet function, the
detrimental effect of thrombocytopenia or prolonged use of antiplatelets
may be specially detrimental for elderly COVID-19 patients. Therefore,
it is fundamental to better understand how to dissociate the prothrom-
botic/proinflammatory mechanisms of platelets from those that protect
against vascular leakage so as to be able to strengthen the latter pharma-
cologically to safeguard the endothelial barrier in the pulmonary micro-
circulation in patients with acute inflammation at high risk of a severe
course of COVID-19 disease. Better understanding of these seemingly
opposite, but well-orchestrated facets of platelet function might pave
the way for future therapies mimicking platelet-dependent mechanisms
maintaining endothelial barrier homeostatis in acute hyperinflammation
syndromes such as COVID-19.
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